By Olivia Bugault

 

Roche Holding AG said Tuesday that its Ocrevus treatment reduces the risk of needing a walking aid in relapsing multiple sclerosis patients by 49%, according to new data.

The analysis from six years of phase 3 open-label extension studies shows that Ocrevus reduces the risk of disease and disability progression for relapsing and primary progressive multiple sclerosis, the Swiss pharmaceutical giant said.

Multiple sclerosis is a disease that occurs when the immune system abnormally attacks the insulation and support around nerve cells in the central nervous system, causing inflammation and other damage, Roche said.

 

Write to Olivia Bugault at olivia.bugault@wsj.com

 

(END) Dow Jones Newswires

April 28, 2020 02:10 ET (06:10 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Roche (QX) Charts.